
The FDA has approved Novartis’ Signifor (pasireotide) for the treatment of a rare and life-threatening hormonal disorder. The US Food …

Pfizer will co-develop and commercialise OPKO’s growth hormone deficiency (GHD) drug hGH-CTP in a new agreement between the firms. The …
Lilly have entered into a worldwide licensing agreement with Australian-based Acrux for Axiron, an experimental under-arm testosterone applicator.The treatment is …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

